Presents recent studies aimed at investigating efficient quality control methods to ensure both the radionuclidic purity of generator eluates, and the proper preparation of new target specific 188Re and 90Y radiopharmaceuticals for various clinical applications.

Summarizes the current status and future trends in the development of radiopharmaceuticals for sentinel lymph node detection (SLND), an essential diagnostic tool for the effective treatment of superficial cancers such as breast tumours and melanoma.